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OBJECTIVE — Littleinformationisavailableontheimpactofabnormalglucosetolerance
on mortality in South Asian and African populations in the developing world. We explored
this issue in a large, multiethnic cohort from the developing nation of Mauritius.
RESEARCH DESIGN AND METHODS — Population-based surveys were under-
taken in 1987, 1992, and 1998. The 9,559 participants (20–82 years old) comprised 66%
South Asian (Indian), 27% Creole (African), and 7% Chinese descent. Mortality was ascer-
tained in 2007.
RESULTS — Overamedian15.1-yearfollow-up,1,557participantsdied.Comparedwith
those with normal glucose tolerance, the all-cause mortality hazard ratios (HR) for known
diabetes, newly diagnosed diabetes, and impaired glucose tolerance were 3.35 (95% CI
2.77–4.04), 2.11 (1.73–2.57), and 1.53 (1.26–1.87) in South Asians and 2.14 (1.65–2.79),
1.41 (1.06–1.88), and 1.08 (0.83–1.40) in Africans, respectively. Those with impaired
fasting glucose were not at increased risk in either ethnicity. In the Chinese, only those with
known diabetes were at increased risk of mortality with HR 3.68 (1.87–7.25).
CONCLUSIONS — This is the ﬁrst study in a developing country of the impact of glucose
intolerance on mortality in an African population, and one of the ﬁrst studies of a South Asian
population. It shows that the impact on mortality in these populations in Mauritius is compa-
rable to that seen in developed countries. These results are important in a global context for
future health policy in light of the impact of the rapid increase in prevalence of diabetes,
especially in developing nations.
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S
eventy percent of adults with diabe-
tes live in the developing world,
with India being the country with
the largest number of people with diabe-
tes (1). However, although data showing
that diabetes is associated with a two to
threefold increased risk of all-cause and
cardiovascular (CVD) mortality in Eu-
ropid populations are abundant (2,3),
there are few or no such data for Africans
and only scant data for South Asian pop-
ulationslivinginthedevelopingworld.In
South Asians, data are limited to pooled
analyses of diabetes and mortality from
the Diabetes Epidemiology Collaborative
Analysis of Diagnostic Criteria in Asia
(DECODA) collaboration (4). Within this
collaboration, South Asians from two
studies, a 5-year follow-up of mortality
from the same cohort of Mauritians used
inthecurrentanalysisandasmallerstudy
of Fijian Indians followed over 8 years,
were included. We are not aware of any
prospective data on effects of type 2 dia-
betesonmortalityinAfricanslivinginthe
developing world.
The developing world imposes a very
differentenvironmentfromthatofthede-
veloped world. There are also differences
in health care systems and delivery, and
thereisagreaterburdenofcommunicable
disease. Given these differences, data on
the association between diabetes and
mortality (total and CVD) collected from
developedcountriescannotreadilybeex-
trapolated to developing countries. Un-
derstanding the relationship of diabetes
and mortality in the context of develop-
ment is of paramount importance to in-
form decision makers of developing
countries about the likely socioeconomic
impact of diabetes in the future.
In this study we used national, popu-
lation-based prospective data from Mau-
ritius, a country that includes people of
South Asian (Indians), African (Creoles),
and Chinese ancestry to investigate the
relationship of diabetes and abnormal
glucose tolerance with all-cause and CVD
mortality.
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METHODS— Mauritius is a subtrop-
icalislandlocatedintheSouthwesternIn-
dian Ocean with a population of 1.3
million. The population is 68% South
Asian (Indian) origin, 3% Chinese origin,
2% Franco Mauritians, and 27% Creole
(people predominantly of African origin
from Madagascar, Mozambique, Malawi,
Tanzania, and Zambia). In 1987, 1992,
and1998,population-basedsurveyswere
conducted using similar standardized
protocols. Details of the survey method-
ology and data collection have been pub-
lished previously (5,6). In 1987, 11
randomly selected (with probability pro-
portional to size) population clusters
were surveyed. In 1992 and 1998, all
original participants, plus any new resi-
dents of the original clusters were invited
forfurthersurveys.Threeadditionalclus-
ters were added in 1992 and resurveyed
in 1998. These extra clusters were in-
cluded to increase representation of the
African population and to assess whether
trends in disease and risk factor contribu-
tion observed in the original study cohort
also occurred in these three new clusters
(6). A total of 9,559 individuals were re-
cruited over the three surveys, and 60%
participated in more than one survey
(28% in all three surveys). The response
rates for these surveys were all 85% (5).
In 2007, a mortality follow-up study of
all participants used an interviewer-
administered survey at the household
level. Where contact with the participant
was not possible, the next of kin or other
household members were interviewed.
Forthosewhocouldnotbetraced,athor-
ough search was conducted by interview
with neighbors and relatives and tracing
within the national death registry to ob-
tain vital status, cause of death, or migra-
tion status. The correct identity of each
participant was validated using previ-
ously known information. Informed and
written consent was obtained from all
participants. The follow-up protocol was
reviewed and approved by the ethics
committee of the Ministry of Health and
Quality of Life, Mauritius.
Risk factors at baseline
In brief, in each survey, eligible adults at-
tended a survey site after an overnight
fast. Weight, height, and waist and hip
circumferences were measured. In 1987,
waist circumference was measured at the
narrowest point between the umbilicus
and xiphoid process and in 1992 and
1998 at the midpoint between the iliac
crest and lower margin of the ribs, and,
thus, the 1987 waist circumference mea-
surement was adjusted by adding 1.5 and
2.7 cm for men and women, respectively
(7). Data on education, smoking, ethnic-
ity,andleisuretimephysicalactivitywere
collected by trained interviewers. Educa-
tion was classiﬁed as primary school/
never attended school or high school
education or higher. Fasting serum sam-
ples for lipids were collected, and an oral
glucose tolerance test was undertaken.
Glucose assays and adjustments have
been described previously (5). Glucose
tolerance status was determined accord-
ing to 1999 World Health Organization
criteria (8). Diabetes was classiﬁed on the
basis of fasting plasma glucose (FPG)
7.0 mmol/l or 2-h plasma glucose
11.1 mmol/l or current treatment with
insulin or oral hypoglycemic agents. Par-
ticipants reporting a history of diabetes
and taking hypoglycemic medication or
those with fasting and/or 2-h plasma glu-
cose in the diabetes range were labeled as
knowndiabetes(KDM).Participantswith
other cases of diabetes were labeled as
newly diagnosed diabetes (NDM). Cases
of diabetes were almost exclusively type 2
(9).Forothers,FPG7.0mmol/land2-h
plasma glucose 7.8 mmol/l but 11.1
mmol/l indicated impaired glucose toler-
ance (IGT), FPG 6.1–6.9 mmol/l and 2-h
plasma glucose 7.8 mmol/l indicated
impaired fasting glucose (IFG), and both
FPG 6.1 mmol/l and 2-h plasma glu-
cose 7.8 mmol/l indicated normal glu-
cose tolerance (NGT).
Causes of death
Among the 1,557 deaths, death certiﬁ-
cates were available for 1,228 partici-
pants, relatives gave information for
1,319participants,andhospitalﬁleswere
retrieved and adjudicated for 460 ran-
domly chosen participants. No informa-
tion was available for 30 deaths, other
than notiﬁcation of death by the next of
kin.BecauseICDcodingwasnotavailable
for deaths before 2005, causes of death
were classiﬁed by study physicians into
11 groups: cardiac (n  586, 38%), cere-
brovascular (n  228, 15%), cancer (n 
199,13%),trauma(n62,4%),diabetes
(n  25, 2%), respiratory disease (n 
104, 7%), hypertension (n  7, 1%), re-
nal failure (n  85, 6%), gastrointestinal/
hepatic/alcohol (n  98, 6%), other (n 
81, 5%), and not known (n  82, 5%).
We deﬁned CVD mortality to include
deathscategorizedascardiac,cerebrovas-
cular, hypertension, and renal failure as
the primary cause of death. The accuracy
of cause of death ascribed on the death
certiﬁcate in the three groups (cardiovas-
cular, cancer, and other) was compared
with that adjudicated by study physicians
using hospital records.
Statistical analyses
Characteristics of the participants are de-
scribed by the mean  SD, median (25th
and 75th percentile), and percentages.
The censoring date for all-cause mortality
wasthedatethattheparticipantornextof
kin was interviewed or the date of death,
whichever occurred ﬁrst. Ascertainment
of mortality or other exit status (i.e., cen-
sored/lost to follow-up) of all participants
was ascertained between 2 April 2007
and 31 October 2007. Participants who
attended only one survey and then were
lost to follow-up (vital status at follow-up
was missing) were excluded (n  467).
For both all-cause and CVD mortal-
ity, we used the proportional hazards
model (Cox model) with age as the time
scale and with glucose tolerance status
and all covariates updated at each survey
forthosepresentatmorethanonesurvey.
The proportionality assumptions re-
quiredforproportionalhazardsmodeling
for the exposures of diabetes were met.
The population attributable fraction
for diabetes and all-cause mortality was
calculated for each sex by the following
formula (10):
PARi 
piRRi  1
1 j1
5 pjRRj  1
where pi is the proportion of individuals
in the ith of ﬁve groups (1  NGT, 2 
IFG, 3  IGT, 4  NDM, and 5  KDM)
and RRi is the mortality rate ratio in each
of these groups compared with that of
those with normal glycemia, so RR1  1.
Analyses were performed with Stata sta-
tistical software (version 10.0; StataCorp,
College Station, TX).
RESULTS— At follow-up, 7,182
(75%) participants were alive, 1,557
(16%) were deceased, and 820 (9%) were
losttofollow-up.Amongthoselosttofol-
low-up, 353 attended at least two surveys
and were censored, and 467 who at-
tended only one survey were excluded,
leaving a total study population of 9,092.
The median follow-up time was 15.1
(0.12–20.5) years, and the crude death
rate was 11.5 (95% CI 11.0–12.1) per
1,000 person-years. The baseline charac-
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follow-up are shown in Table 1.
The proportion of all deaths contrib-
uted to by diabetes (KDM and NDM) was
15%inmenand17%inwomen.Causeof
deathwasavailablefor1,527ofthe1,557
deaths. The CVD mortality rate was 6.7
(95%CI6.3–7.2)per1,000person-years.
A total of 906 (58%) deaths were due to
CVD (65% coronary heart disease, 25%
cerebrovascular disease, 1% hyperten-
sion, and 9% renal failure). Of all deaths
due to CVD, 62% (562 of 906) occurred
in individuals with abnormal glucose me-
tabolism at baseline. The percent agree-
ment of cause of death ascribed on the
death certiﬁcate with that adjudicated by
study physicians using hospital records
was 63%, with no signiﬁcant difference
betweenthosewithandwithoutdiabetes.
Figure 1 shows the hazard ratios
(HRs) with 95% CI by glucose tolerance
categories compared with NGT for all-
cause and for CVD mortality, separately
forthethreeethnicgroups.Withinethnic
groups, the relative impact of diabetes
and other categories of abnormal glucose
tolerance on mortality was similar for
both outcomes. South Asians with IGT,
NDM, and KDM were at higher risk of
all-cause mortality than those with NGT;
the increased risk in individuals with IFG
was of borderline signiﬁcance. For those
of African descent, only NDM and KDM
had a signiﬁcantly higher all-cause and
CVD mortality risk compared with NGT.
In the Chinese, only those with KDM
were at a signiﬁcantly increased risk of
all-cause or CVD death. There was a sig-
niﬁcantly greater impact of diabetes
(KDM and NDM) on all-cause and CVD
mortality among South Asians than
among Africans (interaction term: all-
cause mortality, P  0.003; CVD, P 
0.032). The number of deaths among the
Chinese was too small to draw ﬁrm con-
clusions about differences from other
groups.
Inbothsexes,comparedwiththoseof
South Asian descent, Africans had a sim-
ilarriskofall-causemortalityandChinese
hadasigniﬁcantlylowerall-causemortal-
ityrate,afteradjustmentforotherriskfac-
tors (Table 2). Compared with men with
NGT,menwithKDM,NDM,andIGThad
a signiﬁcantly increased risk of all-cause
mortality. In women, only those with
KDM or NDM were at increased risk for
all-cause mortality.
For CVD mortality, in multiple-
adjusted analyses, NDM and KDM were
risk factors in both sexes. IGT was a risk
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 1985factor for CVD mortality in men only (Ta-
ble 2). When the CVD analysis was re-
peated using CVD deaths coded from
death certiﬁcation only and not adjudi-
cated deaths, the ﬁndings were not mate-
rially different.
In a sensitivity analysis that assumed
participantswithmissingfollow-upinfor-
mationwerealiveatthelastdayoffollow-
up:theHRs(95%CI)forIFG,IGT,NDM,
andKDMformenwere1.10(0.80–1.52),
1.39 (1.21–1.71), 2.03 (1.65–2.49), and
3.12 (2.53–3.86). For women, the corre-
sponding values were 0.94 (0.58–1.51),
1.22 (0.97–1.53), 1.51 (1.18–1.95), and
2.33 (1.88–2.90).
CONCLUSIONS— With the current
high prevalence of diabetes and the pre-
dicted dramatic increase in the number of
individuals with diabetes in many develop-
ingnations,studiesofoutcomesofdiabetes,
particularly morbidity and mortality be-
come of prime importance. This study is
one of the ﬁrst to examine the impact of
diabetes on all-cause and CVD mortality
over the long term in a developing nation.
We showed that there was a greater impact
of diabetes on all-cause and CVD mortality
among South Asians than among Africans.
All-cause mortality risk in those with KDM,
comparedwiththatinthosewithNGT,was
approximately doubled in Africans and in-
Figure 1—Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic
group.HRsareadjustedforpriorCVD,education,sex,hypertension,waistandhipcircumference,smoking,HDLcholesterol,triglycerides,andtotal
cholesterol.
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1986 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.orgcreased31⁄2timesinAsianIndiansandChi-
nese.Furthermore,therewasan40–50%
increased mortality from CVD and all
causes for South Asians with IGT, whereas
in Africans with IGT mortality was not sig-
niﬁcantly increased. Mortality in individu-
alswithIFGwasnotincreasedinanyethnic
group.Wealsoshowedthat62%ofallCVD
deaths occurred in individuals with abnor-
mal glucose regulation (KDM, NDM, IFG,
orIGT)atbaseline.Ofalldeaths,15–17%
of all deaths were attributed to diabetes
(KDM and NDM).
Many studies have demonstrated that
diabetes is an important risk factor for
both all-cause and CVD mortality in Eu-
ropidpopulations(11–13).Therearealso
studiesofindividualsofAfricanoriginliv-
ing in developed countries. The Chicago
Heart Association Detection Project in In-
dustry Study showed that among 666 Af-
rican American men, both asymptomatic
and clinical diabetes were associated with
an increased risk of death with relative
risks of 1.37 (95% CI 0.85–2.20) and
1.78 (0.97–3.25) after adjustment for
conventional risk factors over a period of
22years(11).InanotherstudyofAfricans
from Barbados, those with diabetes had a
HR for all-cause and CVD mortality of
1.80 (95% CI 1.53–2.11) and 2.10
(1.69–2.59), respectively, over a fol-
low-up period of 9 years (14). There are,
however,nodataaboutdiabetesandmor-
tality in Africans living in developing
countries. In the DECODA study, the HR
for KDM for Asians of 3.22 (2.50–4.14)
was similar to our estimate for South
Asians and Chinese (4). DECODA in-
cludes data from a shorter follow–up (5
years) of Mauritians from our study pop-
ulation.IntheAsiaPaciﬁcCohortCollab-
oration, a pooling project that includes
studies from Southeast Asia (Japan, Hong
Kong, Taiwan, Korea, and China), New
Zealand, and Australia, the HRs associ-
ated with diabetes for all-cause mortality
forsouth-eastAsiansandnonAsianswere
1.62 and 1.76, lower than our estimates
(15).
Our ﬁndings that IGT but not IFG is
associated with an increased risk of mor-
tality are consistent with several studies
(2,4,16). The Diabetes Epidemiology:
Collaborative Analysis of Diagnostic Cri-
teriainEurope(DECODE)andDECODA
studies have demonstrated that when 2-h
plasmaglucoseelevationiscontrolledfor,
fasting glucose within the nondiabetic
range is not associated with increased
mortality (2,4). Contrasting ﬁndings in-
clude those of Coutinho et al. (16), who
showed that IFG was signiﬁcantly associ-
ated with fatal and nonfatal CVD events
but were unable to separate IFG from di-
abetes and IGT based on 2-h plasma glu-
cose. Barr et al. (3) showed that IGT was
associated with all-cause but not CVD
mortalityandthatIFGpredictedall-cause
andCVDmortality,butthefollow-upwas
only 5 years. We found no evidence of an
impact of IFG on all-cause or CVD mor-
tality in any ethnic group. The reasons for
the discrepancy among study ﬁndings is
not known but could be due to differ-
ences in the populations studied, the
study design, or the length of follow-up.
The proportion of all deaths contrib-
uted to by diabetes (KDM and NDM) of
15% in men and 17% in women, in this
study is higher than has been reported in
other studies. In the Asia Paciﬁc Cohort
Collaboration, the overall population at-
tributable fraction of diabetes ranged
from 2.3 to 12.2% for coronary heart dis-
ease and was reported to be 6% for all-
cause mortality in Thailand (17). Our
ﬁgure of 15–17% highlights the possible
beneﬁt of initiating lifestyle-based or
pharmaceutical intervention, especially
in the light of recent evidence of the efﬁ-
cacy of lifestyle intervention for diabetes
(18–20).
Several studies have shown that ab-
normal glucose metabolism is present in
approximatelytwo-thirdsofpatientswith
acute myocardial infarction or coronary
artery disease (3,21,22). In the current
analysis, we have shown that 62% of all
CVD deaths occurred in those with either
diabetes, IFG, or IGT at baseline. This
ﬁnding suggests that the public health
beneﬁts of targeting CVD prevention for
those with pre-diabetes and the early
stages of type 2 diabetes would probably
be of great beneﬁt. Such strategies are
underpinned by evidence from trials
(18,20,23).
The strengths of this study include a
large national, population-based sample
with excellent response rates and an ex-
tremely low loss to follow-up of 8.6%.
Sensitivity analyses, which assumed that
all participants who were lost to fol-
low-up were alive at the last day of mor-
tality ascertainment, showed that the HR
for all-cause mortality across the spec-
Table 2—Adjusted HRs (95% CI) for all-cause and CVD mortality in the total population according to sex
Baseline characteristic
HRs (95% CI)
All-cause mortality CVD mortality
Men Women Men Women
Number of deaths (n/N) 892/4,171 665/4,921 517/4,171 389/4,921
Ethnicity
South Asian 1.00 1.0 1.0 1.0
African 1.07 (0.91–1.26) 0.86 (0.71–1.03) 0.86 (0.70–1.07) 0.74 (0.57–0.95)
Chinese 0.60 (0.47–0.78) 0.62 (0.41–0.92) 0.35 (0.23–0.54) 0.48 (0.26–0.87)
Glucose tolerance status
NGT 1.00 1.00 1.00 1.00
IFG 1.13 (0.82–1.56) 0.90 (0.56–1.45) 1.24 (0.82–1.87) 0.66 (0.32–1.38)
IGT 1.39 (1.12–1.71) 1.21 (0.96–1.53) 1.37 (1.02–1.83) 1.16 (0.84 –1.59)
NDM 2.00 (1.63–2.46) 1.56 (1.22–2.01) 2.04 (1.56–2.67) 1.78 (1.29–2.46)
KDM 3.29 (2.68–4.03) 2.51 (2.03–3.11) 3.66 (2.82 –4.73) 3.11 (2.37–4.08)
Data were analyzed using a proportional hazards model (Cox-model) with age as the time scale and with glucose tolerance and all covariates updated at each survey
forthosepresentatmorethanonesurvey.Thosewhoweremissingatfollow-upanddidnotcontributeanyfollow-upinformation(n467)wereexcluded,whereas
thosewhoattendedmorethanonesurveybutwhosevitalstatuscouldnotbeascertainedwerecensored(n353).HRsareadjustedforwaistandhipcircumference,
smoking, hypertension, ethnicity, prior CVD, education, HDL cholesterol, triglycerides, and total cholesterol.
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differed little from the point estimates of
the primary analyses, indicating the ro-
bustness of the ﬁndings of this study.
This study is not without limitations.
Cause of death was ascertained by death
certiﬁcates, hospital records, and next of
kin.Further,inMauritius,informationon
death certiﬁcates was not ICD9 or ICD10
codedandwasnotavailableelectronically
before 2005; thus, ICD codes were un-
available for this study. Instead, causes of
death were coded into broad categories
based on the text written on death certif-
icates. It is possible that some misclassiﬁ-
cation has occurred. It is important to
note that this limitation only affects the
CVD mortality data and not the all-cause
mortality data. However, adjudication of
causeofdeathof19%ofdeathsusinghos-
pital records compared with text on the
death certiﬁcate showed good agreement.
Furthermore, in sensitivity analyses, the
CVD ﬁndings are not materially changed
when cause of death coding was based on
thedeathcertiﬁcateorinformationonthe
certiﬁed extract of death. Finally, the
small number of Chinese participants
limits our ability to provide any certainty
regarding the HR estimates for this ethnic
group.
In summary, the impact of diabetes
on all-cause and CVD mortality in South
Asians and Africans living in a developing
country is just as large as it is in the de-
veloped world. Health policy and plan-
ning agencies in developing countries
need to recognize and plan for the rapid
emergence and escalation of noncommu-
nicable diseases, especially diabetes and
CVD,withthelatterlikelytobeasimpor-
tant a component of the disease spectrum
in developing countries as it is in devel-
oped countries.
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